Abstract

BackgroundArtesunate-amodiaquine (AS-AQ) was introduced in Ghana as the first line drug for treatment of uncomplicated malaria in 2004. We report the perceptions of malaria and malaria treatment behaviour, the community awareness of and perceptions about AS-AQ two years after the introduction of this ACT treatment for malaria.MethodsTwo surveys were conducted; a cross-sectional survey of 729 randomly selected household heads (urban-362, rural-367) and 282 women with children < 5 years (urban-121, rural-161) was conducted in 2006. A district wide survey was conducted in 2007 to assess awareness of AS-AQ. These were complemented with twenty-eight focus group discussions (FGDs) and 16 key informant interviews (KII) among community members and major stakeholders in the health care delivery services. All nine (9) health facilities and five (5) purposively selected drug stores were audited in order to identify commonly used anti-malarials in the study area at the time of the survey.ResultsMajority of respondents ( > 75%) in the sampled survey mentioned mosquito bites as the cause of malaria. Other causes mentioned include environmental factors (e.g. dirty surroundings) and standing in the sun. Close to 60% of the household heads and 40% of the care-givers interviewed did not know about AS-AQ. The community respondents who knew about and had ever taken AS-AQ perceived it to be a good drug; although they mentioned they had experienced some side effects including headaches and body weakness. Co-blistered AS-AQ was available in all the government health facilities in the study area. Different formulations of ACTs were however found in urban chemical shops but not in rural chemical stores where monotherapy antimalarials were predominant.ConclusionThe knowledge of fever as a symptom of malaria is high among the study population. The awareness of AS-AQ therapy and its side-effect was low in the study area. Community education and sensitization, targeting all categories of the population, has to be intensified to ensure an efficient implementation process.

Highlights

  • Artesunate-amodiaquine (AS-AQ) was introduced in Ghana as the first line drug for treatment of uncomplicated malaria in 2004

  • Poor perceptions about malaria and poor malaria drug treatment practices have contributed to widespread resistance of Plasmodium falciparum malaria to commonly used monotherapy such as chloroquine and sulfadoxinepyrimethamine leading to challenges in the control of malaria [7]

  • Respondents in the focus group discussions had similar social characteristics as respondents in the quantitative survey as they were invited from the same communities

Read more

Summary

Introduction

Artesunate-amodiaquine (AS-AQ) was introduced in Ghana as the first line drug for treatment of uncomplicated malaria in 2004. Poor perceptions about malaria and poor malaria drug treatment practices have contributed to widespread resistance of Plasmodium falciparum malaria to commonly used monotherapy such as chloroquine and sulfadoxinepyrimethamine leading to challenges in the control of malaria [7]. Artemisinin-based combination therapy (ACT) has been demonstrated to remarkably improve treatment efficacy [8] and are currently recommended by the World Health Organization to overcome the problem of drug resistance and for effective control of malaria [9]. The perceptions of malaria and community treatment seeking behaviour have been widely investigated in relation to monotherapies, mainly chloroquine and sulphadoxinepyrimethamine in Ghana and other African countries. Understanding the perceptions of malaria, treatment behaviour, awareness of and prompt access to the new and effective ACT drugs are deemed important steps to malaria control and elimination

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call